Plasma Cell Immunophenotyping Improve Prognostic Stratification of Multiple Myeloma Patients

Meddour, Yanis; Rahali, M.C.; Belakehal, Salah Eddine; Benfenatki, N.; Ardjoune, F.Z.; Chaib, Samia; Djidjik, Réda

doi:10.5812/ijcm.5350

Cited by 4 publications

(8 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

Section: Factores Asociados Con Las Características Del Tumor Inmunofenotipounclassified

“…El perfil de expresión antigénica de las células plasmáticas neoplásicas es heterogéneo (31) . Se ha evaluado el impacto de los niveles de expresión de antígenos aberrantes en la mediana de supervivencia de pacientes con mieloma múltiple (31) . Meddour et al encuentran que los pacientes con mieloma múltiple que eran CD45-/CD19-/CD56+/CD27-con alto recuento de células plasmáticas (mayor a 10 % CD38+/CD138+) tenían una supervivencia menor, y los que presentaban combinaciones de cuatro o cinco de estos antígenos aberrantes, tenían un pronóstico desfavorable, un sistema de estadificación internacional de alto riesgo (III), Durie y Salmon estadio III, valores más bajos de hemoglobina y niveles elevados de beta 2 microglobulina (31) .…”

Section: Factores Asociados Con Las Características Del Tumor Inmunofenotipounclassified

“…Se ha evaluado el impacto de los niveles de expresión de antígenos aberrantes en la mediana de supervivencia de pacientes con mieloma múltiple (31) . Meddour et al encuentran que los pacientes con mieloma múltiple que eran CD45-/CD19-/CD56+/CD27-con alto recuento de células plasmáticas (mayor a 10 % CD38+/CD138+) tenían una supervivencia menor, y los que presentaban combinaciones de cuatro o cinco de estos antígenos aberrantes, tenían un pronóstico desfavorable, un sistema de estadificación internacional de alto riesgo (III), Durie y Salmon estadio III, valores más bajos de hemoglobina y niveles elevados de beta 2 microglobulina (31) . Del mismo modo, Paiva et al demuestran que la presencia de CD19 y CD28, así como la ausencia de CD117 en células plasmáticas neoplásicas, estaba asociado a tasas de supervivencia global y libre de progresión significativamente más cortas (32) .…”

Section: Factores Asociados Con Las Características Del Tumor Inmunofenotipounclassified

See 2 more Smart Citations

Factores pronósticos que afectan la supervivencia en el paciente con mieloma múltiple

Cuervo-García

Arbeláez

Cárdenas

2021

CES Med

View full text Add to dashboard Cite

El mieloma múltiple es la segunda neoplasia hematológica más frecuente y se caracteriza por la expansión aberrante de las células plasmáticas monoclonales, en la mayoría de los casos con la producción de una paraproteína anormal conocida como proteína monoclonal o por evidencia de daño orgánico, manifestado por hipercalcemia, insuficiencia renal, anemia o lesiones óseas. Los factores pronósticos han evolucionado desde la caracterización de la carga tumoral utilizando el sistema de estadificación Durie y Salmon y el sistema de estadificación internacional, hasta el análisis molecular y el perfil de expresión génica, debido al reconocimiento de aberraciones cromosómicas y moleculares que desempeñan un papel en el desarrollo del mieloma múltiple y la progresión del mismo. El sistema de estadificación internacional se revisó en 2015 agregando anormalidades genéticas de alto riesgo, tales como la presencia de mutaciones t(4;14), t(14;16) y del(17p) junto con la adición de la deshidrogenasa láctica. Es así como, a lo largo del tiempo, se han identificado factores pronósticos importantes de esta neoplasia que se encuentran asociados al huésped y al microambiente tumoral, además de variables clínicas y anormalidades de las células tumorales.

show abstract

Section: Factores Asociados Con Las Características Del Tumor Inmunofenotipounclassified

See 1 more Smart Citation

Factores pronósticos que afectan la supervivencia en el paciente con mieloma múltiple

Cuervo-García

Arbeláez

Cárdenas

2021

CES Med

View full text Add to dashboard Cite

show abstract

“…The main immunophenotypic markers with prognostic implications, which were previously described in MM include CD27, CD28, CD45, CD56, CD117 and β2-microglobulin [12,22,25]. CD27, a transmembrane phosphoglycoprotein member of tumor necrosis factor (TNF) family is expressed in normal plasma cells Submit your Manuscript | www.austinpublishinggroup.com [26,27].…”

Section: Introductionmentioning

confidence: 99%

“…This marker is frequently downregulated in MM plasma cells [28]. Its expression is involved in PCs differentiation [25] and is associated with higher survival rates [28,29]. On the other hand its absence leads to disease progression [30,31].…”

Section: Introductionmentioning

confidence: 99%

Immunophenotypic Markers Associated with Minimal Residual Disease Status and Outcome in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Missassi¹,

MRV²,

CM³

et al. 2021

annhematoloncol

View full text Add to dashboard Cite

Multiple Myeloma (MM) is one of the most common hematologic malignancies, with a heterogeneous prognosis. Therefore, the recognition of biomarkers can be useful to understand the differences in patient outcomes. Minimal Residual Disease (MRD) has been considered a very important prognostic factor in MM. In parallel, the prognostic value of immunophenotypic markers expressed in MM Plasma Cells (PCs) has also been described. The aim of this study was to assess the impact of CD27, CD28, CD45, CD56, CD117 and β2-microglobulin expressions on the outcome of 154 MM patients undergoing Autologous Stem Cell Transplantation (ASCT). The relation of each marker studied with the Overall Survival (OS) and Progression-Free Survival (PFS) was assessed, alone and in association with pre-ASCT MRD. Scores of good (GPM) and poor Prognostic Markers (PPM) were established, according to their respective survival curves. The expressions of CD27 and CD45 were associated to longer OS (p=0.013 and p=0.00, respectively) and PFS (p=0.00) as well as the absence of CD28 (OS p=0.026; PFS p=0.001) and CD56 (OS p=0.004; PFS p=0.009), in patients with undetectable MRD. The number of GPM showed an inverse correlation with the level of MRD (p=0.04), while a higher number of PPM was observed in patients with higher levels of MRD (p=0.04), which were also significantly associated with OS and PFS. In conclusion, although pre-ASCT MRD is a powerful prognostic factor in MM, these biomarkers can provide additional prognostic information and be used in the follow-up of MM patients.

show abstract

Immunophenotypic expression profile of multiple myeloma cases at a tertiary hospital in Nairobi Kenya

Mengich,

Rajput,

Malkit

et al. 2023

Front. Med.

View full text Add to dashboard Cite

IntroductionMultiple myeloma (MM) is a plasma cell neoplasm that constitutes 10–15% of all hematopoietic neoplasms. Kenya is placed among the top five African countries for MM incidence and MM-related mortality. Prior studies have suggested that the aberrant expression of Cyclin D1, CD56, CD117 and Ki-67 on neoplastic plasma cells is useful in disease prognostication. The prevalence and significance of expression of these markers in a cohort of MM cases in Kenya has not been studied previously.MethodsA retrospective cross-sectional study was carried out at the Aga Khan University Hospital, Nairobi. The study population included 83 MM cases with available trephine blocks archived between 1st of January 2009 and 31st of March 2020. Immunohistochemical expression of Cyclin D1, CD56, CD117, and Ki-67 was analyzed and scored. The biomarkers were described using frequencies based on the positive and negative results. Fisher’s exact test was used to determine the association between the immunophenotypic markers and categorical variables.ResultsOf the 83 selected cases, expression of Cyclin D1, CD56, CD117 and Ki-67 was identified in 28.9, 34.9, 7.2, and 50.6%, respectively. Cyclin D1 positivity was significantly associated with hypercalcemia. Absence of CD117 expression was noted to be associated with adverse risk parameters including an IgA isotype or light chain disease, International Staging System (ISS) stage III disease, abnormal baseline serum free light chains (sFLC) and a high plasma cell burden.ConclusionCyclin D1 expression was congruent with previously reported studies. The frequency of CD56 and CD117 expression was lower than previously reported. This may be due to differences in disease biology between the study populations. Approximately half of cases were Ki-67 positive. Our data showed limited associations between the expression of studied markers and clinicopathologic variables. However, this could be attributed to the small study sample size. We would recommend further characterization of the disease in a larger prospective study with the inclusion of survival outcomes and cytogenetic studies.

show abstract

Plasma Cell Immunophenotyping Improve Prognostic Stratification of Multiple Myeloma Patients

Cited by 4 publications

References 33 publications

Factores pronósticos que afectan la supervivencia en el paciente con mieloma múltiple

Factores pronósticos que afectan la supervivencia en el paciente con mieloma múltiple

Immunophenotypic Markers Associated with Minimal Residual Disease Status and Outcome in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplantation

Immunophenotypic expression profile of multiple myeloma cases at a tertiary hospital in Nairobi Kenya

Contact Info

Product

Resources

About